irasia.com


Mesoblast Limited

Board and Management Team

Board of Directors

Brian Jamieson, FCA (Non-Executive Chairman)
William M. Burns, BA (Vice Chairman) (Appointed on 1 September 2016)
Silviu Itescu, MBBS, FRACP (Chief Executive Officer and Executive Director)
Donal O'Dwyer, BE, MBA (Non-Executive Director)
Eric A. Rose, MD (Non-Executive Director) (Appointed on 17 April 2013)
Michael Spooner, BCom, ACA, MAICD (Non-Executive Director)
Ben-Zion Weiner, BSc, MSc, PhD (Non-Executive Director) (Appointed on 10 May 2012)
Charlie Harrison, BA, LLB (Hons) (Company Secretary) (Appointed on 1 September 2014)

Management Team

Silviu Itescu, MBBS, FRACP (Chief Executive Officer & Managing Director)
Paul Hodgkinson, MA (Hons), FCA (Chief Financial Officer) (Appointed on 25 August 2014)
Roger D. Brown, BA (Spinal Orthopedic Disorders)
Peter Howard, BSc, LLB (Hons) (Corporate Executive & General Counsel)
John D. McMannis, PhD (Manufacturing)
Julie Meldrum, Inv Rel (AIRA) (Global Corporate Communications)
Michael Schuster, MS, MBA (Pharma Partnering)
Karen Segal, PhD (Diabetes and Metabolic Diseases)
Paul J. Simmons, PhD (Research and New Product Development)
Donna Skerrett, MD, MS (Chief Medical Officer)
Geraldine Storton, BSc, MMS, MBA (Head of Regulatory Affairs & Quality Management)
Eric Strati, Pharm.D., MBA (Commercial)
Jonathan R. Symonds, CBE, BA, FCA (Corporate Finance & Strategy) (Appointed on 11 March 2014)


Board of Directors

Mesoblast Board of Directors: Ben-Zion Weiner, Eric Rose, Silviu Itescu, Brian Jamieson (Chairman), Michael Spooner, Bill Burns and Donal O'Dwyer.

  Brian Jamieson, FCA
Non-Executive Chairman

Mr Jamieson has served on the Board of Directors as Chairman since 2007 after retiring as Chief Executive of Minter Ellison Melbourne. Previously he was CEO at KPMG Australia, a KPMG Board Member in Australia, and a member of the USA Management Committee. He is Chairman of Sigma Pharmaceuticals Ltd, a Non-Executive Director of the Tatts Group Ltd, and Director and Treasurer of the Bionic Ear Institute. He is a fellow of the Institute of Chartered Accountants in Australia and a Member of the Institute of Company Directors.

back to top

 
  William M. Burns, BA (Appointed on 1 September 2016)
Vice Chairman

Mr Burns has served on the Board of Directors since 2014. He has spent his entire management career at the Beecham Group and F. Hoffmann-La Roche Ltd. Mr Burns was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F. Hoffmann-La Roche Ltd. until he retired in 2014. He has also served on the Board of Directors of Chugai Pharmaceutical Co. and Genentech from 2002 to 2014, and Crucell from 2010 to 2011. Mr Burns is also a member of the Oncology Advisory Board of the Universities of Cologne/Bonn. He is the Chairman of the Board of Directors of Biotie Therapies Corp. and is a Non-Executive Director of Shire PLC. In October 2014, Mr Burns was appointed a trustee of the Institute of Cancer Research, London, UK.

back to top

 
  Silviu Itescu, MBBS, FRACP
Chief Executive Officer and Executive Director

Dr Itescu has served on the Board of Directors since the Company's founding in 2004, was Executive Director from 2007, and became Chief Executive Officer and Managing Director in 2011. Prior to founding Mesoblast in 2004, he established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. In 2011, he was named BioSpectrum Asia Person of the Year. Dr Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the Board of Directors of several publicly-listed life sciences companies.

back to top

 
  Donal O'Dwyer, BE, MBA
Non-Executive Director

Mr O'Dwyer has served on the Board of Directors since 2004. He has over 25 years of experience as a senior executive in the global cardiovascular and medical devices industries. From 1996 to 2003, Mr O'Dwyer worked for Cordis Cardiology, the cardiology division of Johnson & Johnson's Cordis Corporation, initially as its president (Europe) and from 2000 as its worldwide president. Prior to joining Cordis, he worked with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences. He is a qualified civil engineer, has an MBA and is on the Board of Directors of a number of life sciences companies including Cochlear Limited, Atcor Medical Holdings Ltd and Fisher & Paykel Healthcare Ltd.

back to top

 
  Eric A. Rose, MD, (Appointed on 17 April 2013)
Non-Executive Director

Dr Rose has served on the Board of Directors since 2013. He is currently Chairman and Chief Executive Officer of SIGA Technologies and Executive Vice President, Life Sciences at MacAndrews & Forbes, Inc., the holding company of Ronald O. Perelman. From 2008 through 2012, Dr Rose served as the Edmond A. Guggenheim Professor and Chairman of the Department of Health Evidence and Policy at the Mount Sinai School of Medicine. From 1994 through 2007, he served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. From 1982 through 1992, Dr Rose led the Columbia Presbyterian heart transplantation program in the United States. He currently sits on the Board of Directors of ABIOMED.

back to top

 
  Michael Spooner, BCom, ACA, MAICD
Non-Executive Director

Mr Spooner has served on the Board of Directors since 2004. During this period he has filled various roles including as Chairman from the date of the ASX public listing in 2004 until 2007, Chair of the Audit and Risk Committee as well as a member of the Remuneration Committee. Over the past several years Mr Spooner has served on the Board of Directors in various capacities at several Australian and international biotechnology companies, including BiVacor Pty Ltd (2009-2013), Advanced Surgical Design & Manufacture Limited (2010-2011), Peplin, Inc. (2004-2009), Hawaii Biotech, Inc. (2010-2012), Hunter Immunology Limited (2007-2008), and Ventracor Limited (2001-2003). Prior to returning to Australia in 2001, he spent much of his career internationally where he served in various roles including as a partner to PA Consulting Group, a United Kingdom-based management consultancy and a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong. In addition, Mr Spooner has owned and operated several international companies providing services and has consulted to a number of American and Asian public companies.

back to top

 
  Ben-Zion Weiner, BSc, MSc, PhD
Non-Executive Director

Dr Weiner has served on our Board of Directors since 2012. In a 37-year career at Teva Pharmaceutical Industries Ltd, he held various senior research and development positions, including Senior Vice President of Global Research and Development. Dr Weiner twice received the Rothschild Prize for industrial innovation - for the development of Copaxone for the treatment of multiple sclerosis, and alpha D3 for kidney and bone disorders. He is on the Board of Directors at Novaremed Ltd., the scientific advisory board at E-QURE Corp. and Breed IT, Corp. and has served on the Board of Directors at Geffen Biomed Investments Ltd (2010-2013), XTL Biopharmaceuticals Limited (2012-2013) and Breed IT, Corp.

back to top

 
  Charlie Harrison (Appointed on 1 September 2014)
Company Secretary

Mr Harrison joined Mesoblast as a legal counsel in 2013. He was previously a senior associate at the international law firm Allens, working in their Hong Kong and Melbourne offices for nine years as a corporate lawyer. Mr Harrison has an Arts/Law degree from the University of Melbourne. He was appointed Company Secretary in 2014.

back to top

 

Management Team

Mesoblast has a highly experienced management team made up of individuals who have held senior positions in international pharmaceutical and biotechnology companies. This team is responsible for the strategic direction, operations and success of our company.

  Silviu Itescu, MBBS, FRACP
Chief Executive Officer & Managing Director

Dr Itescu has served on Mesoblast's Board of Directors since the Company's founding in 2004, was Executive Director from 2007, and became Chief Executive Officer and Managing Director in 2011. Prior to founding Mesoblast in 2004, he established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. In 2011, he was named BioSpectrum Asia Person of the Year. He has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the Board of Directors of several publicly listed life sciences companies.

back to top

 
  Paul Hodgkinson, MA (Hons), FCA (Appointed on 25 August 2014)
Chief Financial Officer

Mr Hodgkinson joined Mesoblast in 2014 as Chief Financial Officer. He has 16 years of international pharmaceutical experience in the areas of finance, strategic planning, business development and licensing, manufacturing and supply chain, and procurement. From 2011 through 2014, Mr Hodgkinson served as the Country Chief Financial Officer for the Novartis Australia and New Zealand, or ANZ, group of companies and divisions, which was comprised of Alcon, Sandoz, and the Novartis Vaccines and Diagnostics, Consumer Health, Animal Health, and Pharmaceuticals divisions. Previously he held a number of leadership roles with AstraZeneca in the UK, including Global Licensing Finance Director, before serving as CFO for AstraZeneca Australia from 2006-2011. Mr Hodgkinson is a member of the Institute of Chartered Accountants in Australia, is a Fellow of the Institute of Chartered Accountants of England and Wales and has a Masters in Engineering from Cambridge University. He has also undertaken executive leadership programs at the Harvard Business School and INSEAD.

back to top

 
  Roger D. Brown, BA
Spinal Orthopedic Disorders

Prior to joining Mesoblast in 2009, Mr Brown served as the Divisional Vice President, Clinical, Regulatory and Quality for Abbott Laboratories' Spine Division. He has over 20 years of regulatory, clinical, product development, quality and reimbursement experience dealing with a variety of technologies from physiological monitoring equipment to implantable and biological products. Mr Brown has also held clinical and regulatory roles at Axiomed Spine Corporation, Wright Medical Technology, CryoLife and Nellcor Puritan Bennett. He received a Bachelor of Arts from Missouri's William Jewell College and completed coursework at Oxford University in England.

back to top

 
  Peter Howard, BSc, LLB (Hons)
Corporate Executive & General Counsel

Mr Howard has been integrally involved with Mesoblast since its inception in 2004, when he played a critical role in the corporate structuring and listing of Mesoblast on the ASX. More generally, he has extensive experience with many biopharmaceutical firms and major research institutions, covering public listings, private financings, strategic, licensing, intellectual property and mergers and acquisition activities. Mr Howard has done so in several roles, including as a partner at a major law firm, entrepreneur, director and senior executive.

back to top

 
  John D. McMannis, PhD
Manufacturing

Dr McMannis has 27 years of experience in clinical cellular therapy trials in both academic and commercial environments. Before joining Mesoblast in 2011, he served at the University of Texas MD Anderson Cancer Center as a Professor of Medicine from 1999 to 2011, and as the Director of the Cell Therapy Laboratory from 1999 to 2011, and as the Technical Director of the Cord Blood Bank from 2008 to 2011. Before his tenure at the University of Texas MD Anderson Cancer Center, Dr McMannis was a Senior Director Technical Affairs at the Immunotherapy Division of Baxter and Therapy Scientist at COBE BCT (now Terumo BCT). He has served on the scientific advisory boards at BioSafe SA, Biolife Solutions, Inc., and General Electric and on the board of directors for the American Association of Blood Banks, or AABB, and the National Marrow Donor Program, or NMDP, which operates the "Be the Match" donor program.

back to top

 
  Julie Meldrum, Inv Rel (AIRA)
Global Corporate Communications

Ms Meldrum joined Mesoblast in 2004. She has deep and diverse experience as a corporate communications strategist, European foreign correspondent, political and business reporter and television and radio producer. Ms Meldrum also served as a senior diplomat for 14 years promoting Australian policies and industries in the key markets of Japan, Hong Kong and Indonesia and has advised Prime Ministers, Cabinet Ministers and business leaders. She has been the recipient of the League of American Communication Professionals Gold Magellan Award, the United Nations Media Peace Prize for Radio, was a Governor of the Foreign Correspondents' Club in Hong Kong and a Director of Australian Doctors International. Ms Meldrum is senior advisor to the Washington DC-based Alliance for Regenerative Medicine's Communications and Education Committee.

back to top

 
  Michael Schuster, MS, MBA
Pharma Partnering

Mr Schuster, who joined Mesoblast in 2004, leads the Company's partnering discussions. Previously he was the head of the Company's investor relations outreach program and was part of the founding executive team at both Mesoblast Limited and Angioblast Systems, Inc. Mr Schuster was Executive Vice President of Global Therapeutic Programs from 2010 to 2013 and was the Director of Business Development and Vice President of Operations from 2004 to 2010. He holds an undergraduate degree in science from Tufts University, a Master's degree in Immunology & Microbiology from New York Medical College, and a MBA from Fordham University in New York.

back to top

 
  Karen Segal, PhD
Diabetes and Metabolic Diseases

Before joining Mesoblast in 2011, Dr Segal established herself as a senior academic investigator for more than 15 years in diabetes, metabolism and obesity at Columbia University's College of Physicians and Surgeons, Mount Sinai School of Medicine, and Weill Cornell Medical College. Prior to joining Mesoblast, she worked for 15 years in leadership roles at Hoffmann La Roche and at Sanofi-Aventis in global clinical development and medical affairs for programs in diabetes and metabolism.

back to top

 
  Paul J. Simmons, PhD
Research and New Product Development

Prior to joining Mesoblast in 2011, Dr Simmons had nearly 30 years of experience in stem cell research, especially research in basic hematopoiesis and in precursor cells for the stromal system of the bone marrow. He served as President of the International Society of Stem Cell Research from 2006 to 2007. Dr Simmons held the C. Harold and Lorine G. Wallace Distinguished University Chair at the University of Texas Health from 2008 to 2011 and served as the inaugural Professor and Director of the Centre for Stem Cell Research at the Brown Foundation Institute of Molecular Medicine from 2006 to 2011. He is, or has served as, an associate editor, a member of the editorial board, or a reviewer on multiple scientific and medical journals including Experimental Hematology, Cytotherapy and Stem Cell Research, Cell Stem Cell, Stem Reports, Science and Nature.

back to top

 
  Donna Skerrett, MD, MS
Chief Medical Officer

Dr Skerrett, who has more than 20 years of combined experience in transfusion medicine, cellular therapy, and transplantation, has held executive roles at Mesoblast since 2004. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York from 2004 to 2011, and served as Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University's New York-Presbyterian Hospital from 1999 to 2004. Dr Skerrett has been an advisor to the New York State Department of Health on the Progenitor Cell Committee since 1989, Chair of the Governor's Council on Blood and Transfusion Services since 2007, and serves on the Executive Committee of the Alliance for Regenerative Medicine. From 2004, she held roles at Mesoblast in clinical and regulatory affairs until she was appointed Chief Medical Officer in 2011.

back to top

 
  Geraldine Storton, BSc, MMS, MBA
Head of Regulatory Affairs & Quality Management

Ms Storton is a seasoned pharmaceutical executive with more than 24 years' experience across the full value chain of Pharmaceutical and Medical Device Research and Development, production and commercialization worldwide. She has an extensive background in regulatory affairs and quality, most recently as a consultant to cell therapy companies. Prior to this, Ms Storton held executive roles at Hospira, and its predecessor companies in both regulatory affairs and quality, with a focus on major program management. As Vice President, Program Management, Quality, at Hospira headquarters in Chicago, she led a company-wide quality remediation program to improve compliance in manufacturing across 15 facilities worldwide. As Regional Director, Commercial Quality ANZ, Asia and Japan, Ms Storton was responsible for quality oversight and management of all products sold in Asia Pacific countries. Her responsibilities included regulatory compliance, batch release, field actions, complaints management, change control, due diligence and new product launch. As director of global regulatory operations, Ms Storton managed development and registration of new products and on-market management of the existing product portfolio for all Hospira's products developed or manufactured within Asia Pacific for global distribution. She joined Mesoblast in December 2015.

back to top

 
  Eric Strati, Pharm.D., MBA
Commercial

Eric Strati has over 17 years of experience across a broad range of industries within the healthcare sector including pharmaceutical, biotechnology, investment banking, and pharmacy benefit management. Prior to joining Mesoblast in 2015, Dr Strati held various commercial leadership roles including new product planning, lifecycle management, sales, marketing, and payer strategy. Previous positions include most recently as Executive Director, Managed Markets at Novartis, medical affairs positions at Genzyme and Bristol-Myers Squibb, and Vice President of Global Pharmaceutical Equity Research at HSBC. He earned his Bachelors of Science in Pharmacy and MBA in Health Systems Management from Union University, and Doctor of Pharmacy from University of Kansas.

back to top

 
  Jonathan R. Symonds, CBE, BA, FCA (Appointed on 11 March 2014)
Corporate Finance and Strategy

Mr Symonds, who was Chief Financial Officer of Novartis AG from 2009 to 2013, became an advisor to Mesoblast in 2014. Prior to joining Novartis, Mr Symonds was a Partner and Managing Director of Goldman Sachs Group Inc (2007-2009), Chief Financial Officer of AstraZeneca plc (1997-2007) and a Partner of KPMG (1992-1997). In 2014, he was appointed an independent non-executive Director of HSBC Holdings plc and Chairman of HSBC's European subsidiary, HSBC Bank plc. He is a non-executive Director of Genomics England Limited. Previous roles include non-executive Director of Diageo plc and Qinetiq plc., Chairman of the 100 Group of Finance Directors, Joint Chairman of the Business Tax Forum, board member of the Accounting Standards Board, and founder of the Oxford University Centre for Business Taxation Research, all in the United Kingdom. In 2007, Mr Symonds was awarded a Commander of the British Empire for service to industry.

back to top

 

updated 2nd November, 2016


  • Company's Index
  • irasia.com

  • © Copyright 1996-2019 irasia.com Ltd. All rights reserved.
    DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website.
    TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited.
    TERMS OF USE: Please read the Terms of Use governing the use of our website.